Many cancer and metabolism related networks were found to be involved after treatment with the drugs but only two pathways were altered by the combination treatment and not by MP or rapamycin alone: the MAPK and the epidermal growth factor receptor (ErbB) signaling pathways (Table 1). Here, EGFR is linked to cancer.